Status:
COMPLETED
A Study Evaluating the Long-term Safety of VX-445 Combination Therapy
Lead Sponsor:
Vertex Pharmaceuticals Incorporated
Conditions:
Cystic Fibrosis
Eligibility:
All Genders
12+ years
Phase:
PHASE3
Brief Summary
This study evaluated the long-term safety and tolerability of elexacaftor (ELX), tezacaftor (TEZ), and ivacaftor (IVA) triple combination (TC) treatment in participants with cystic fibrosis (CF).
Eligibility Criteria
Inclusion
- Currently participating in study VX17-659-105 (NCT03447262)
Exclusion
- History of drug intolerance in study VX17-659-105 that would pose an additional risk to the participant in the opinion of the investigator
- Current participation in an investigational drug trial (other than study VX17-659-105)
- Other protocol defined Inclusion/Exclusion criteria may apply.
Key Trial Info
Start Date :
August 9 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 14 2022
Estimated Enrollment :
458 Patients enrolled
Trial Details
Trial ID
NCT04043806
Start Date
August 9 2019
End Date
December 14 2022
Last Update
July 6 2023
Active Locations (97)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35233
2
Stanford University
Palo Alto, California, United States, 94304
3
Children's Hospital Colorado
Aurora, Colorado, United States, 80045
4
Hartford Hospital
Hartford, Connecticut, United States, 06102